|
Researchers Firm-Up Evidence For Role Of Mitochondria In Parkinson's Disease |
 |
 |
|
Parkinsons Articles -
New Information
|
|
Written by Unknown
|
|
Monday, 15 February 2010 20:00 |
|
A new study from the National Institutes of Health sheds light on the functions of two proteins related to Parkinson's disease, called parkin and PINK1... |
|
PET Scan Improves Diagnosis of Parkinsonism |
|
|
|
News -
Latest
|
|
Written by Randy Dotinga
|
|
Tuesday, 12 January 2010 18:27 |
PET Scan Improves Diagnosis of Parkinsonism  Early Identification Then Leads to Better Treatment, Researchers Say(HealthDay News) - New research shows that PET brain scans can diagnose which type of Parkinson's-related disease a person has. Between 1998 and 2006, researchers scanned the brains of 167 patients who had signs of Parkinsonism but hadn't been specifically diagnosed. They used PET (positron emission tomography) technology. The researchers found that the scans allowed them to differentiate between idiopathic Parkinson's disease, multiple system atrophy and progressive supranuclear palsy, although the diagnoses sometimes differed from those of doctors who assessed the patients. |
|
|
|
|
News -
Latest
|
|
Written by NewYork-Presbyterian/Weill Cornell
|
|
Tuesday, 12 January 2010 18:35 |
Reducing Dosage of Parkinson's Drugs Can Cause Symptoms Similar to Those of Cocaine Withdrawal In a World First, Researchers Identify and Define Dopamine Agonist Withdrawal Syndromeor DAWS
NewYork-Presbyterian/Weill Cornell Study Explains Difficulties in Tapering Parkinson's Drugs in Patients With Side Effects Such as Compulsive Eating, Pathological Gambling, Compulsive Buying and Hypersexuality (HealthNewsDigest.com) - NEW YORK -- New research has shown that reducing the dosage of dopamine agonist (DA) drugs, a mainstay treatment for Parkinson's disease (PD), sometimes causes acute withdrawal symptoms similar to those reported by cocaine addicts -- including anxiety, panic attacks, depression, sweating, nausea, generalized pain, fatigue, dizziness and drug cravings. These symptoms can be severe, and are not alleviated by other PD medications.
For the first time, researchers have defined this phenomenon, which they call dopamine agonist withdrawal syndrome, or DAWS. Led by a physician-scientist at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, the study is reported in the Jan. 11 Archives of Neurology.
|
|
|
|
|
Written by DENISE GRADY
|
|
Monday, 30 November 2009 12:02 |
Regimens: Withdrawal Warning on Parkinson’s Drugs Some people with Parkinson’s disease develop severe withdrawal symptoms when they try to taper off a widely used type of Parkinson’s drug, researchers are reporting. The drugs, called dopamine agonists, include pramipexole, sold as Mirapex, and ropinirole, sold as Requip. They help control the movement problems caused by Parkinson’s, but may cause other troubles in some patients — including impulse control disorders, in which people compulsively eat, gamble or shop. |
|
Last Updated on Tuesday, 12 January 2010 18:31 |
|
|
|
|
Written by University of Florida.
|
|
Sunday, 10 May 2009 08:49 |
Doctors Test Targets For Deep Brain Stimulation In Parkinson Surgery ScienceDaily (Mar. 19, 2009) — Doctors may be able to tailor a specialized form of brain surgery to more closely match the needs of Parkinson patients, according to results from the first large-scale effort to compare the two current target areas of deep brain stimulation surgery, or DBS. . Called the COMPARE Trial, the National Institutes of Health-funded study conducted at the University of Florida evaluated 45 patients for mood and cognitive changes related to DBS. UF investigators found that DBS in either brain target effectively treated motor symptoms such as tremors, stiffness and slowness. However, DBS also produced unique effects depending on the target location, especially in patients' moods and mental sharpness. . The discoveries, in the March 13, 2009 issue of Annals of Neurology, may have an impact on the selection of DBS patients, especially those with pre-existing memory, cognitive or mood disabilities. |
|
Hormones May Play a Role in Parkinson's |
|
|
|
News -
Latest
|
|
Written by Kathleen Doheny
|
Hormones May Play a Role in Parkinson's. Study Shows Length of Fertility for Women May Be a Factor in Risk for Parkinson's Disease By Kathleen Doheny
.
Feb. 25, 2009 -- Women who are fertile for more than 39 years and have natural menopause have a reduced risk of developing Parkinson's disease, according to a new study, while women with four or more pregnancies have a higher risk. . Parkinson's disease is a movement disorder that results in slowness of movement, impaired balance, and tremor and trembling in the extremities and face. It affects about 1 million Americans, according to the Parkinson's Disease Foundation. |
|
Gene Protects Against Neurotoxins That Spur Inflammation And Parkinson's Disease |
|
|
|
About Parkinsons -
The Project
|
|
Written by Cathleen Genova
|
Gene Protects Against Neurotoxins That Spur Inflammation And Parkinson's Disease. A new study in the April 3rd issue of the journal Cell, a Cell Press publication, helps to explain why people who carry mutations in a gene known as Nurr1 develop a rare, inherited form of Parkinson's disease, the most prevalent movement disorder in people over the age of 65. . They have found evidence that the gene normally acts to suppress an inflammatory response and, in turn, the production of neurotoxins in the brain. Those neurotoxins can otherwise spawn the damage to dopaminergic neurons that is characteristic of Parkinson's disease. The findings not only offer new insight into the causes of the disease, but also may point to new avenues for therapy, according to the researchers. |
|
|
Amicus Therapeutics Presents Positive Data Update From Phase 2 Extension Study Of Amigal(TM) For Fabry Disease |
|
|
|
Parkinsons Articles -
New Information
|
|
Written by Unknown
|
|
Thursday, 11 February 2010 21:00 |
|
Amicus Therapeutics (Nasdaq: FOLD) announced additional positive preliminary data from its ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease at the Lysosomal Disease Network WORLD Symposium in Miami, Florida... |
OCALA, FLORIDAMY RECOMMENDATION FOR AN OUTSTANDINGDOCTOR Highly Recommended Doctor William Gaya, MD PA Being a patient of Doctor Gaya I can say that he is the best doctor I have treated with for my Parkinson's Disease. He is professional but very very personable. Doctor Gaya always greets you with a smile and will take the time to answer your questions. I would highly recommend Doctor Gaya for any neurological needs. If you are living in the Marion County area or planning on moving to Marion County or Ocala, Florida and need a neurologist please look up Doctor Gaya you will not regret it. .
Bruce Bouley |
|
|
|
|
Written by Teva Pharmaceutical Industries Ltd.
|
|
Monday, 16 November 2009 00:00 |
FDA Approves Newly Revised Prescribing Information For AZILECT(R) Reducing Medication And Food Restrictions Teva Pharmaceutical Industries, Ltd. (NASDAQ: TEVA) announced the U.S. Food and Drug Administration (FDA) approved the newly revised prescribing information for AZILECT® (rasagiline tablets) reducing medication and food restrictions. This update was based on clinical data that confirmed the mechanism of action of AZILECT® as a selective MAO-B (monoamine oxidase-B) inhibitor at the recommended doses of 1 mg and 0.5 mg.
The newly approved prescribing information reflects reduced concerns regarding the use of AZILECT® together with certain medications, including many over-the-counter cough/cold medications. In addition, patients taking AZILECT® no longer need to follow a general dietary restriction of ordinary levels of tyramine, an amino acid found in certain foods and beverages, such as air-dried and fermented meats, aged cheeses and most soybean products. However, due to potential mild increased sensitivity in some patients, ingestion of very high levels of tyramine (e.g., >150 mg) should be avoided by patients taking MAO inhibitors. |
|
|
|
|
Written by The University of Florida Health Science Center
|
University Of Florida To Lead National Effort To Help Patients With Rare Brain Disease Even with devastating brain diseases such as Alzheimer's and Parkinson's, doctors can reach into their medical bags to find something to help a patient.
But they come up empty-handed when they try to help the vast majority of patients with ataxia - disabling disorders that rob people of their balance and coordination.
University of Florida neurologists are trying to change that with the help of a $1 million Challenge grant from the National Institute of Neurological Disorders and Stroke to establish a nationwide network of physician-scientists with expertise in clinical ataxia research. |
|
|
|
|
The Project
|
|
Thursday, 13 August 2009 00:00 |
|
PARKINSON'S DISEASE - RISK FACTORS - CAUSES A genetic predisposition for Parkinson's disease is possible. In a small number of cases of Parkinson's disease worldwide, there is a strong inheritance pattern for the disorder. In these cases, the onset of the disease and its gradual development depend on a trigger, such as trauma, other illness, or exposure to an environmental toxin. The risk for Parkinson's increases with age and the disease generally manifests in the middle or later years of life. Causes The cause of Parkinson's disease is unknown. Many researchers believe that a combination of several factors is involved in the development of Parkinson's. These factors include free radicals, accelerated aging, environmental toxins, and genetic predisposition. |
|
|
|
|
Written by Depomed
|
|
Thursday, 13 August 2009 00:00 |
Depomed Reports Encouraging Results Of Its Phase I Trial For DM-1992 Program In Parkinson's Disease Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson's patients, DM-1992, Depomed's investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa's efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.
One of Depomed's formulations in the study extended the median time point at which levodopa blood levels exceeded the efficacious threshold of 300 ng/mL to approximately nine hours, compared to approximately seven hours for the generic version of Sinemet CR tested in the study. The time to median peak levodopa blood levels in the study was extended to four hours, compared to 2.8 hours for the comparator. DM-1992 was well tolerated in the study.
|
|
